Abstract:Nathalie LeVasseur 1,2 , Karen A. Gelmon 1,2^ 1 Division of Medical Oncology, BC Cancer, Vancouver, BC, Canada; 2 Department of Medicine, University of British Columbia, Vancouver, BC, Canada ^ ORCID: 0000-0003-4111-2757. Comment on: Rodler E, Sharma P, Barlow WE, et al . Cisplatin with veliparib or placebo in metastatic triple-negative breast cancer and BRCA mutation-associated breast cancer (S1416): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol 2023;24:162-74. Keywords: Poly (ADP-ribose) polymerase (PARP); BRCA-like; veliparib; homologous recombination deficiency (HRD); biomarker Submitted Feb 14, 2023. Accepted for publication Oct 18, 2023. Published online Jan 29, 2024. doi: 10.21037/tcr-23-577 Triple negative breast cancers (TNBCs) have long been associated with aggressive disease biology and a worse prognosis in the setting of advanced breast cancer (ABC). Despite advances in the treatment with protocols using immunotherapy and novel antibody drug-conjugates (ADCs), there remains an unmet need for patients with advanced TNBC. Homologous recombination deficiency (HRD) represents a disruption in the usual DNA repair process by the homologous recombination repair (HRR) pathway. The BRCA 1 and BRCA 2 genes are centrally involved in the double-strand DNA break repair process and pathogenic germline BRCA1 and BRCA2 mutations are identified in 10–20% of patients with TNBC, presenting a potential therapeutic target (1). The EMBRACA and the Olympiad studies sought to compare the efficacy of the PARP inhibitors talazoparib and olaparib, respectively, to standard chemotherapeutic agents in patients with ABC and germline mutations in BRCA1/2. Both studies established the role of poly (ADP-ribose) polymerase (PARP) inhibitors for the treatment of advanced HER2-negative breast cancer harbouring a pathogenic BRCA mutation, with a nearly 3-month progression-free survival (PFS) advantage and a doubling of the overall response rate (ORR) with talazoparib and olaparib, relative to standard single-agent chemotherapy (2,3). Additionally, combinations of veliparib with platinum doublet chemotherapy have previously shown an improvement in PFS in patients with pathogenic germline BRCA mutations, with minimal increase in hematological toxicity, in contrast to combination studies with other PARP inhibitors (4). Given the relatively low frequency of pathogenic BRCA1/2 germline mutations, it remains uncertain whether there is a potential role for PARP inhibitors in germline BRCA wildtype patients with evidence of HRD, although benefits have been demonstrated in similar populations with ovarian and prostate cancer (5). The HRD phenotype is observed when there is a significant disruption in the usual DNA repair process by the HRR pathway. This is typically mediated through loss of function mutations in key genes, namely BRCA1 and BRCA2 , but may also involve other genes including PALB2 , ATM , RAD51 , amongst others, and can also be caused by epigenetic modification such as hypermethylation of the BRCA1 promoter region (6). There has been speculation that 40–60% of TNBCs may express a BRCA-like phenotype in the absence of pathogenic BRCA mutations (7). However, the definition of HRD and refinement of what defines a BRCA-like phenotype remains ambiguous and the use of this as an informative biomarker to guide treatment in breast cancer has not proven fruitful thus far. In the study accompanying this editorial published in Lancet Oncology in January 2023, Rodler et al. report the results of the S1416 randomized double-blind, placebo-controlled phase 2 study of cisplatin 75 mg/m 2 with either veliparib 300 mg twice daily on days 1–14 or placebo for each 21-day cycle (8). Following randomisation, central testing was performed using the BROCA-HR test as the first step, which comprises a group of 40 genes with recognized involvement in hereditary breast and ovarian cancer or HRR. Patients were subsequently assigned to a BRCA 1/2-mutated, BRCA-like or non-BRCA like group ( Figure 1 ). BRCA-like was defined using 4 markers, in rank order of priority, comprising either a genomic instability score of 42 or higher based on the myChoice CDX Plus assay from Myriad, a somatic BRCA1/2 mutation, BRCA1 promoter hypermethylation or germline mutations in HRR genes other than BRCA. Those assigned to the BRCA-like group had a median PFS of 5.9 months in the cisplatin and veliparib group versus 4.2 months in the cisplatin and placebo group, with a statistically significant hazard ratio of 0.57. In contrast, the patients in the non-BRCA like group derived no further benefit from the addition of veliparib, with a median PFS of 3–4 months. This study is of interest for a num -Abstract Truncated-

How far does a new horizon extend for rucaparib in metastatic prostate cancer?

A Phase II Study of Rucaparib Monotherapy in Nonmetastatic, Hormone-Sensitive Prostate Cancer Demonstrating “BRCAness” Genotype (ROAR)

A phase II study of maintenance rucaparib in patients with platinum sensitive, advanced pancreatic cancer and a pathogenic germline or somatic variant in BRCA1, BRCA2 or PALB2: A four year survival update.

PARP Inhibitors in Metastatic Prostate Cancer: Evidence to Date

Response to Rucaparib in BRCA-Mutant Metastatic Castration-Resistant Prostate Cancer Identified by Genomic Testing in the TRITON2 Study

Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: Analysis From the Phase II TRITON2 Study

Rucaparib for the Treatment of Metastatic Castration-resistant Prostate Cancer Associated with a DNA Damage Repair Gene Alteration: Final Results from the Phase 2 TRITON2 Study

BRCAAway: A randomized phase 2 trial of abiraterone, olaparib, or abiraterone + olaparib in patients with metastatic castration-resistant prostate cancer (mCRPC) bearing homologous recombination-repair mutations (HRRm).

A case report of a dramatic response to olaparib in a patient with metastatic pancreatic cancer harboring a germline BRCA2 mutation.

First-line PARP inhibitors (PARPi) with androgen receptor pathway inhibitors (ARPi) in metastatic castration-resistant prostate cancer (mCRPC): A systematic review and meta-analysis.

Clinical Pharmacokinetics and Pharmacodynamics of Rucaparib

PARP Inhibitors in Metastatic Prostate Cancer: A Comprehensive Systematic Review and Meta-analysis of Existing Evidence

Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer

PARP Inhibitors in Metastatic Castration-Resistant Prostate Cancer: Unraveling the Therapeutic Landscape

Synthetic Lethality Beyond BRCA: A Phase I Study of Rucaparib and Irinotecan in Metastatic Solid Tumors With Homologous Recombination-Deficiency Mutations Beyond BRCA1/2

Abstract 1066: PARP inhibitor rucaparib in combination with imipridones ONC201 or ONC212 demonstrates preclinical synergy against BRCA1/2-deficient breast, ovarian, and prostate cancer cells

Efficacy of Poly(ADP-ribose) Polymerase Inhibitors by Individual Genes in Homologous Recombination Repair Gene-Mutated Metastatic Castration-Resistant Prostate Cancer: A US Food and Drug Administration Pooled Analysis

Cost-Effectiveness of Genomic Test-Directed Olaparib for Metastatic Castration-Resistant Prostate Cancer

Durable benefit from poly(ADP-ribose) polymerase inhibitors in metastatic prostate cancer in routine practice: biomarker associations and implications for optimal clinical next-generation sequencing testing

Rucaparib as a Salvage Treatment in Platinum-Sensitive Relapsed Ovarian Carcinoma: A Case Report

Can we successfully define and target BRCA-like breast cancers?